Logo image of CRU

CRUCIBLE ACQUISITION CORP-A (CRU) Stock Fundamental Analysis

NYSE:CRU - New York Stock Exchange, Inc. - US22877P1084 - Common Stock - Currency: USD

10.05  -0.02 (-0.2%)

After market: 10.05 0 (0%)

Fundamental Rating

1

Taking everything into account, CRU scores 1 out of 10 in our fundamental rating. CRU was compared to 0 industry peers in the Unkown industry. CRU may be in some trouble as it scores bad on both profitability and health. CRU is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CRU was profitable.
In the past year CRU has reported a negative cash flow from operations.
CRU Yearly Net Income VS EBIT VS OCF VS FCFCRU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 0 2M -2M 4M 6M

1.2 Ratios

Industry RankSector Rank
ROA 4.36%
ROE 4.59%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CRU Yearly ROA, ROE, ROICCRU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 0 1 -1 2 3

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CRU so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRU Yearly Profit, Operating, Gross MarginsCRU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for CRU remains at a similar level compared to 1 year ago.
Compared to 1 year ago, CRU has an improved debt to assets ratio.
CRU Yearly Shares OutstandingCRU Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 10M 20M 30M
CRU Yearly Total Debt VS Total AssetsCRU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 50M 100M 150M 200M 250M

2.2 Solvency

CRU has an Altman-Z score of 15.08. This indicates that CRU is financially healthy and has little risk of bankruptcy at the moment.
A Debt/Equity ratio of 0.01 indicates that CRU is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 15.08
ROIC/WACCN/A
WACCN/A
CRU Yearly LT Debt VS Equity VS FCFCRU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 0 50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 0.55 indicates that CRU may have some problems paying its short term obligations.
CRU has a Quick Ratio of 0.55. This is a bad value and indicates that CRU is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.55
Quick Ratio 0.55
CRU Yearly Current Assets VS Current LiabilitesCRU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 200K 400K 600K

More info and screens

0

3. Growth

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-21.19%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 28.71, the valuation of CRU can be described as expensive.
The average S&P500 Price/Earnings ratio is at 26.92. CRU is around the same levels.
Industry RankSector Rank
PE 28.71
Fwd PE N/A
CRU Price Earnings VS Forward Price EarningsCRU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRU Per share dataCRU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CRU!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CRUCIBLE ACQUISITION CORP-A

NYSE:CRU (11/30/2022, 8:26:29 PM)

After market: 10.05 0 (0%)

10.05

-0.02 (-0.2%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.1%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap325.05M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 28.71
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.31
P/tB 1.31
EV/EBITDA N/A
EPS(TTM)0.35
EY3.48%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0
BVpS7.67
TBVpS7.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 4.36%
ROE 4.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.55
Quick Ratio 0.55
Altman-Z 15.08
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-21.19%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A